These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8129865)

  • 1. Class III antiarrhythmics in overdose. Presenting features and management principles.
    Leatham EW; Holt DW; McKenna WJ
    Drug Saf; 1993 Dec; 9(6):450-62. PubMed ID: 8129865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy versus combination therapy with class III antiarrhythmic agents to attenuate transmural dispersion of repolarization: a potential risk factor for torsade de pointes.
    Shah SA; Kluger J; White CM
    Pharmacotherapy; 2007 Sep; 27(9):1297-305. PubMed ID: 17723083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha D
    Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome.
    Riera AR; Uchida AH; Ferreira C; Ferreira Filho C; Schapachnik E; Dubner S; Zhang L; Moffa PJ
    Cardiol J; 2008; 15(3):209-19. PubMed ID: 18651412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotalol: a breakthrough antiarrhythmic?
    Nappi JM; McCollam PL
    Ann Pharmacother; 1993 Nov; 27(11):1359-68. PubMed ID: 8286812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemodynamic effects of antiarrhythmic compounds: intrinsic effects and autonomic modulation.
    Hoffmeister HM; Beyer ME; Seipel L
    Am J Cardiol; 1997 Oct; 80(8A):24G-30G. PubMed ID: 9354409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentially significant drug interactions of class III antiarrhythmic drugs.
    Yamreudeewong W; DeBisschop M; Martin LG; Lower DL
    Drug Saf; 2003; 26(6):421-38. PubMed ID: 12688833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.
    Hohnloser SH
    Am J Cardiol; 1997 Oct; 80(8A):82G-89G. PubMed ID: 9354415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Class III antiarrhythmic drugs].
    Aiba T; Kamakura S
    Nihon Rinsho; 1996 Aug; 54(8):2125-31. PubMed ID: 8810787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol.
    Funck-Brentano C
    Eur Heart J; 1993 Nov; 14 Suppl H():30-5. PubMed ID: 7904936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Class III antiarrhythmic drugs (amiodarone, bretylium and sotalol) on action potentials and membrane currents in rabbit sino-atrial node preparations.
    Satoh H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Dec; 344(6):674-81. PubMed ID: 1775200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A benefit-risk assessment of class III antiarrhythmic agents.
    Brendorp B; Pedersen O; Torp-Pedersen C; Sahebzadah N; Køber L
    Drug Saf; 2002; 25(12):847-65. PubMed ID: 12241126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.
    Fitton A; Sorkin EM
    Drugs; 1993 Oct; 46(4):678-719. PubMed ID: 7506652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Torsade de pointes with amiodarone in a patient with previous torsade during beta-receptor blockade.
    Skanes AC; Morton BC; Green MS; Tang AS
    Can J Cardiol; 1997 Apr; 13(4):383-6. PubMed ID: 9141970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactions between implantable cardioverter-defibrillators and class III agents.
    Movsowitz C; Marchlinski FE
    Am J Cardiol; 1998 Aug; 82(4A):41I-48I. PubMed ID: 9737653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.
    Advani SV; Singh BN
    Drugs; 1995 May; 49(5):664-79. PubMed ID: 7601009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
    Follath F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current classification of anti-arrhythmia agents].
    Weirich J; Wenzel W
    Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.